PLRX Stock Overview
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.
Pliant Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$17.18|
|52 Week High||US$26.25|
|52 Week Low||US$3.97|
|1 Month Change||-23.37%|
|3 Month Change||-14.44%|
|1 Year Change||24.49%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-19.34%|
Recent News & Updates
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?Sep 10
Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?Jul 28
We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn RateApr 22
Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn SituationDec 29
We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business GrowthSep 07
Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%May 17
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMay 13
Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth PlansMar 22
We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory EarningsJan 21
Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?Dec 17
|PLRX||US Pharmaceuticals||US Market|
Return vs Industry: PLRX exceeded the US Pharmaceuticals industry which returned 15% over the past year.
Return vs Market: PLRX exceeded the US Market which returned -17.6% over the past year.
|PLRX Average Weekly Movement||7.8%|
|Pharmaceuticals Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: PLRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: PLRX's weekly volatility has decreased from 25% to 8% over the past year.
About the Company
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis.
Pliant Therapeutics, Inc. Fundamentals Summary
|PLRX fundamental statistics|
Is PLRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PLRX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.31|
|Net Profit Margin||-1,160.53%|
How did PLRX perform over the long term?See historical performance and comparison